We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. RZ402 reduced central subfield thickness at all dose ...

Viking Therapeutics VKTX announced that it has completed enrolling patients in its exploratory maintenance dosing study of ...

Analysis of Annovis Bio's lead product, buntanetap, tested in neurodegenerative diseases suggests questionable efficacy, in our opinion. Recent topline data from the PD phase 3 study shows no efficacy ...

Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in ...

In OASIS 4, a Phase III study conducted outside of the US, the investigational compound elinzanetant met all primary endpoints demonstrating a statistically significant reduction in frequency of ...

A recent study investigated the effectiveness of the augmented binary method for investigating rare diseases in a small sample size. Composite endpoints consider a number of individual outcomes to ...

Patients taking Merck's Vytorin, which combines simvastatin with the non-statin Zetia, experienced fewer major cardiovascular events than patients treated with simvastatin alone, according to the ...

AbbVie ABBV announced that the phase III study — PROGRESS — evaluating its oral calcitonin gene-related peptide (“CGRP”) receptor antagonist, Qulipta (atogepant) — as a preventive treatment for ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the data from its two pivotal Phase 3 immunogenicity and safety trials of Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine ...

The pivotal phase III clinical study shows that the new phosphate binder PA21 successfully controls hyperphosphatemia in patients with chronic kidney disease on dialysis. The study investigated the ...